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Table 2
Test day Day -8 Day 0 Day 14 P for trend
Test 1 Test 2 Post lidocaine Follow-up(post
steroid)
Mean SE Mean SE Mean SE Mean SE
Computer-controlled algometer, kg
Corpus Hoffa 2.4 0.1 2.4 0.1 2.8 0.1 3.2 0.1 <.0001
Vastus lateralis 2.4 0.1 2.5 0.1 2.9 0.1 3.0 0.1 <.0001
Tibialis anterior 2.8 0.1 2.6 0.1 2.8 0.1 3.1 0.1 0.0006
Cuff algometer, kPa
Lower leg 15.6 0.4 15.4 0.4 16.0 0.4 15.9 0.4 0.0214
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S269Purpose: TissueGene-C (TG-C) is a mixture of normal human chon-
drocytes (hChonJ) and genetically modiﬁed chondrocytes to express
TGF-b1 (hChonJb#7), and currently undergoing phase 2 clinical trials
for osteoarthritis. Phase 2a clinical trials have shown that TG-C treat-
ment signiﬁcantly reduced pain when administered to the osteoar-
thritic patients. In this study, we investigated the effect on pain
reduction by the chondrocytes expressing TGF-b (hChonJb#7) which is
a component of TG-C.
Methods: Monosodium iodoacetate (MIA)-induced osteoarthritis rat
model was used in the study. Three milligram of MIA was intra-
articularly injected into the left knee of SD rat (280-300g) to induce
degradation of cartilage (Ponomis et al, Pain; 2005: 339). The rats
showing pain-related behaviors measured by von Frey ﬁlament test
were selected for the evaluation of hChonJb#7. At two weeks post MIA
administration, various doses of hChonJb#7were injected into the same
knee. The effect on the mechanical allodynia by hChonJb#7 treatment
was evaluated by von Frey ﬁlament test. After completing the ﬁlament
tests, the knees were harvested for the histological analysis in the
cartilage.
Results: The improvement of pain related behavior was dose-depen-
dently observed earliest from 1 week post hChonJb#7 injections. The
minimum effective dose was 3 x 10^4 cells of hChonJb#7. The effect was
maintained upto 4 week post hChonJb#7 injections. The histological
analysis showed that the integrity of cartilage was severely affected by
MIA treatment but hChonJb#7 treatment protected the cartilage from
MIA-induced damage when compared with the untreated group.
Conclusions: The current study indicated that the chondrocytes
expressing TGF-b (hChonJb#7) reduced pain in a rat model whichmight
explain pain reduction in osteoarthritis patients demonstrated during
the clinical trials.
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A SELECTIVE CCR2 ANTAGONIST SHOWED MONOCYTES MIGRATION-
INDEPENDENT ANALGESIA IN RAT MODELS OF INFLAMMATORY
PAIN
L. Corradini y, S. Hobbie z, S. Frattini x, B. Stierstorfer z,
H. Doods y. yBoehringer-Ingelheim Pharma GmbH & Co. KG, Dept. CNS
Diseases Res., Biberach an der Riss, Germany; zBoehringer-Ingelheim
Pharma GmbH & Co. KG, Biberach an der Riss, Germany; xBoehringer-
Ingelheim Pharma GmbH & Co. KG, Milan, Italy
Purpose: The aim of this study is to demonstrate whether the Che-
mokine C-C motif (CCR2) receptor is involved in inﬂammatory pain and
which mechanisms could describe its physiological contribution in pain
pathways.
Methods: Compound A was tested for in vitro properties in native cells
(rat whole blood assay) and recombinant cells lines (CHO cells
expressing rat CCR2). Binding assay was performed in rat CCR2 receptor
membrane (RMB) while functional assays were rat whole blood
monocytes shape change and calcium mobilization assay in CHO cell
line. Selectivity over CCR5 was investigated by binding assay on CHO
cells expressing rat CCR5.
To assess the in vivo proﬁle of compound A, adult (200-275 g) male
Wistar-Han (Charles River, Germany) rats undergone intraplantar
injection of complete Freund's adjuvant (CFA, 25ug/ul by Sigma Aldrich)
or intraarticular injection with 1 mg of monosodium iodoacetate (MIA,
50 ul by Sigma Aldrich) for induction of paw inﬂammatory pain or
osteoarthritis (OA), respectively.
Analgesic properties of compound A were assessed by using paw
pressure test (Randall Selitto test, UgoBasile, Italy) at 24 hrs post CFA
injection and by Incapacitance tester (manufactured by Boehringer-Ingelheim) the weight bearing (WB) deﬁcit was assessed at 3 days post
MIA injection. In addition anti-edema properties were investigated in
the CFA model measuring changes in the paw volume as assessed by
pletysmography (UgoBasile, Italy).
Tissues were collected from injured paws or joints, for further histo-
logical examination. All experimental procedures were approved by the
ethics committee and the Regierungspräsidium Tübingen (VVH
06-007).
Results: In rat compound A is a selective CCR2 antagonist with Ki in rat
RMB of 3.6 nM, with no binding properties to the closest homologous
CCR5 (Ki¼2920 nM). In addition, it reversed monocytes shape changes
(IC50 4.3 nM) and inhibited Calcium mobilization in CHO cells
(IC50¼1.4 nM) proving to be a full antagonist devoid of any agonistic
activity.
In the CFA model, Compound A showed a dose dependent anti-hyper-
algesic effect after acute treatment. The highest dose of 10 mg/kg, orally
(PO) achieved full effect comparable to celecoxib (30 mg/kg, PO) while
the minimal effective dose was measured at 1 mg/kg, PO. Moreover,
unlike celecoxib repeated doses of compound A did not prevent edema
formation in the CFA model.
In the MIA model compound A, like celecoxib, showed no effect in the
WB deﬁcit when dosed acutely, however it signiﬁcantly reversed pain-
like behaviour when given by subchronic treatment. Furthermore
histological ﬁndings revealed that compound A has no effect in
reducing monocytes migration in the CFA paw or MIA joint.
Conclusions: Overall our data support a CCR2 antagonist to have the
potential to provide analgesia in nociceptive pain condition. In addition
preclinical data suggest that analgesic properties of CCR2 antagonists in
pain inﬂammatory models can not be attributed to blockage of mono-
cytes migration.
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MEASUREMENT OF PAIN IN AN ACUTE MURINE ARTHRITIS PAIN
MODEL USING A DYNAMIC WEIGHT BEARING DEVICE AND EVOKED
PAIN RESPONSES: EFFECT OF INTRA-ARTICULAR CAPSAICIN
PRETREATMENT
H.E. Krug y,z, C. Dorman z, S. Funkenbusch z, S. Frizelle z,
M. Mahowald y,z. yUniv. of Minnesota, Minneapolis, MN, USA;
zMinneapolis VA Hlth.Care System, Minneapolis, MN, USA
Purpose:Murine models are important to study arthritis pain and new
analgesics, but the measurement of pain in mice is challenging. The
DynamicWeight Bearing (DWB) device measures individual limb forces
and time spent bearing weight on each limb during spontaneous
activity. Evoked pain behaviors in mice are sensitive to change due to
arthritis pain and analgesia. We hypothesized that mice with acute
arthritis would have measurable changes in DWB due to joint pain that
would correlate with evoked pain behaviors and that this could be
prevented by pre-treating with intra-articular (IA) capsaicin. We
measured DWB and Evoked Pain Scores (EPS) in acute arthritis to
determine if DWB correlates with EPS and whether it is a reliable
measure of spontaneous pain behavior in animals with arthritis. To test
the reliability of DWB in differentiating arthritic from nonarthritic
animals, some mice were pretreated with capsaicin to prevent devel-
opment of arthritis. We also measured substance P in the dorsal root
ganglia of animals with andwithout arthritis and withmorphine (MOR)
and capsaicin (CAP) treatment.
Methods: C57Bl6 mice were used for all experiments. Acute inﬂam-
matory arthritis was produced by IA injection of 10ml 2.5% carrageenan
into the left knee 2-4 hours prior to pain behavior testing. Analgesic
controls were injected with 2.5% carrageenan diluted in MOR solution
Mean (SEM) Naive Sham Injected Acute Arthritis MOR Rx Acute Arthritis MOR Alone CAP Pre-treatment CAP Alone Day 6
EPS 0.87 (0.41) 1.67 (0.88) 6.57 (1.01) 0.67 (0.42) 1.88 (0.85) 3.2 (0.58) 1.67 (1.67)
DWB (L/R) % Weight 102.6 (2.47) 96.3 (8.56) 83.7 (5.26) 98.4 (6.35) 96.2 (1.95) 106.4 (7.96) 104.1 (10.59)
DWB (L/R)% Time on Limb 100.6 (0.97) 100.0 (1.60) 94.7 (2.16) 99.9 (0.59) 99.2 (0.80) 99.07(1.98) 101.1 (1.91)
Results (Values in bold and italics p<.05)
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S270(0.15mg/knee). Some mice were injected IA with CAP (0.305 mmol)
7 days before induction of arthritis. DWBwasmeasured with a Dynamic
Weight Bearing apparatus (Bioseb, Vitrolles, France). Evoked pain scores
were derived by tallying ﬁghts + vocalizations/1 minwith repeated ﬁrm
palpation of the knee. Substance P signal intensity from ipsilateral and
contralateral DRGs in the lumbar region were compared by immuno-
histochemistry. Development of inﬂammatory arthritis was conﬁrmed
by histology.
Results: Arthritis pain was clearly and reproducibly indicated by
increased EPS in arthritic mice. DWB was signiﬁcantly reduced by
acute arthritis in the affected limb measured by both % weight bearing
and time on the affected limb. IA MOR improved EPS and DWB by all
measures. Pretreatment with capsaicin abolished the increased EPS
from carrageenan arthritis and normalized DWB by all measures. IA
CAP injection alone had no effect on DWB or EPS by day 6. Substance
P signal intensity appeared to be higher in the ipsilateral DRG
compared to the contralateral in arthritic animals. Articular inﬂam-
mation in CAR induced arthritic mice was not prevented by CAP.-
Conclusions: Pain can be quantitated in murine arthritis models using
measures of DWB and EPS. EPS increased and DWB of the affected limb
decreased signiﬁcantly with acute inﬂammatory arthritis. Analgesia
produced by IA MOR was detected by both DWB and EPS in arthritic
mice. Arthritic animals pretreated with capsaicin did not develop pain
as measured by EPS or DWB though there was histologic evidence for
acute inﬂammation. DWB appears to have signiﬁcant utility for
measuring arthritis pain in animal models. It is sensitive to change, has
good reproducibility between mice and is highly correlated with other
measure of arthritis pain in mice.524
ASSESSING THE EFFICACY OF A VISCOSUPPLEMENT COMBINING
HYALURONIC ACID AND SORBITOL (SYNOLIS-VA) IN PATIENTS
WITH HIGH GRADES KNEE OSTEOARTHRITIS FOR WHOM
CORTICOTHERAPY IS CONTRAINDICATED
M. Bausani. Ortopedia e Traumatologia, Siena, Italy
Purpose: Synolis-VA is an innovative viscosupplement (VS) combining
a high concentration (20 mg/ml) of a > 2 MDa Sodium Hyaluronate
(NaHa) from non animal origin with a high concentration of Sorbitol
(40mg/ml), an oxygen free radical (OFR) scavenger. The strong ability of
Sorbitol to scavenge and neutralize OFR has already been proven to
delay the degradation of the NaHA chains. We hypothesis that the
antioxidant effect of Sorbitol allows reduction of the oxidative stress
affecting chondrocytes and synoviocytes and would therefore play
a fast and durable pain relief effect in patients with high grades knee OA
and with no access to corticotherapy.
Methods: 11 patients with high Kellgren-Lawrence grades symptomatic
Knee OA and contraindication for corticotherapy were included in a 26
weeks prospective open pilot study. Treatment regimen consisted of 3
IA injections of 2 ml of Synolis-VA on week apart. Pain and function
measures using walking pain (WP) 5 points Likert scale (0 to 4),
WOMAC A pain (0 to 20) and WOMAC stiffness (0 to 8) scores were
obtained at W0, W1, W2 and W13 and W26.
Results: 10 patients out of the 11 included in the study were diagnosed
with KL grade IV.
At W0 mean WP was at 3.5, WOMAC pain was 15.2 and WOMAC stiff-
ness was 5.4. At W2, one week after the 2nd Synolis VA injection, re-
ported scores were at their lowest for WP at 2.2 (-37%), WOMAC pain at
10.6 (-32%) and WOMAC stiffness at 2.5 (-53%), with 11 responders. 26
weeks after treatment initiation, scores were still signiﬁcantly
improved forWP at 2.5 (-29%), WOMAC pain at 11.8 (-22%) andWOMAC
stiffness at 3.1 (-43%) with 10 responders, demonstrating prolonged
signiﬁcant activity up to 26 weeks.
Conclusions: This study demonstrates a quick and strong pain relief
occurring immediately after the ﬁrst injection of Synolis-VA. Treat-
ment's beneﬁts were still strongly noticeable at the end of follow-up(W26) despite most of patients diagnosed with Kellgren-Lawrence
grade IV (10 out of 11 patients) and despite the absence of cortico-
therapy.
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PARENTERAL ILOPROST IN THE SYMPTOMATIC TREATMENT OF HIP
OSTEOARTHRITIS
A.-T.D. Magbitang, A. Rubio, M. Tee. Univ. of the Philippines, Philippine
Gen. Hosp., Manila, Philippines
Background: Iloprost is a prostacyclin analogue that has been used in
the treatment of symptomatic bone marrow edema of different
aetiology.
Objective: To present a case of bilateral hip osteoarthritis treated with
intravenous iloprost.
Case: A 32-year old Filipino female presented with pain in the lower
back and bilateral hip of two years duration, precipitated by weight-
bearing activities such as prolonged standing and walking long-
distances, and temporarily relieved by rest. She had no known
co-morbid conditions, denied intake of any herbal or over-the-counter
medications, but had a history of practicing mixed-martial arts for eight
years. Complete blood count, blood chemistries and inﬂammatory
markers were all normal. Radiographs of the hips showed sclerosis on
the superior portion of the left acetabulum consistent with osteode-
generative changes. Magnetic resonance imaging of the hips revealed
subtle heterogenous marrow signals within both acetabulum and
femoral heads with minimal effusion. Bone marrow edema, probably of
osteoarthritic etiology was diagnosed. Beginning avascular necrosis was
also considered.
The patient was given Iloprost 20 ug daily intravenous infusions for six
doses. No untoward event was noted. Hip pain decreased by 50% after
the second dose (from VAS 7/10 to VAS 3/10), and completely resolved
after the ﬁfth dose. The patient was subsequently advised off-loading
for 3 to 4 weeks and was prescribed physical therapy for gait training.
Conclusion: Iloprost is a prostacyclin analogue that may be used in the
symptomatic treatment of bone marrow edema of different causes,
including osteoarthritis.
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QUANTITATIVE PROTEOMIC ANALYSIS OF HUMAN BONE MARROW
MESENCHYMAL STEM CELLS SECRETOME DURING
CHONDROGENESIS
B. Rocha y, V. Calamia y, V. Casas z, L. Lourido y, C. Fernández y,
J. Mateos y, P. Fernández-Puente y, M. Carrascal z, F.J. Blanco y, C. Ruiz-
Romero y. yOsteoarticular and Aging Res. Lab., Proteomics Unit-
Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain;
z Laboratorio de Proteómica CSCIC/UAB, Barcelona, Spain
Purpose: A major limited factor for the application of human bone
marrow mesenchymal stem cells (hBMSCs) in cartilage tissue engi-
neering is our understanding of the process by which cartilage is
developed, termed chondrogenesis. This multi-step process is regulated
by a variety of growth factors, including bone morphogenic proteins
and transforming growth factor b (TGF-b) proteins. In addition, chon-
drogenic differentiation is alsomodulated by extracellular matrix (ECM)
proteins. Considering that the functional role for the majority of these
secreted proteins during chondrogenesis process is not fully estab-
lished, we have applied SILAC (Isotope Labeling by Amino Acids in Cell
Culture) technique to analyze the extracellular protein expression
proﬁle of hBMSCs undergoing chondrogenic differentiation.
Methods: hBMSCs isolated from 3 osteoarthritic (OA) patients were
grown in SILAC DMEM with different isotope variants of lysine and
arginine between 4-6 weeks. The fully labelled cell populations were
then subjected to chondrogenesis under a home-made medium con-
taining 10 ng/ml TGF-b3 and other factors for 14 days. 24 h before
collecting the secretome, the micromasses were carefully washed and
